Supplementary figure 3.

TP53 mutation is associated with FBXW7 genotype regardless of hormone receptor status. cBioPortal was used to query datasets encompassing 4,413 breast cancer patients across three studies for which FBXW7 and TP53 mutational status as well as ER and HER2 status were partially annotated (Supplementary References 22-24). Of the 4,413 total samples, 2,491 were not annotated regarding ER/HER2 status. 1,257 were annotated as ER+/HER2-, 307 as ER-/HER2-, and 198 as HER2+. Regardless of category, patients that harbored a FBXW7 mutation had an increased frequency of TP53 mutations compared to FBXW7 WT patients. The low number of samples harboring both FBXW7 and TP53 mutations per category precluded statistical analysis.